Chinese therapeutics medicine developer Thousand Oaks Biopharmaceuticals Co. announced yesterday that they have completed a RMB300 million (US$43.61 million) series A round of financing, led by New Alliance Capital, according to a company statement. Other investors including venture capital firm Addor Capital, TenYall&Sumin Investment Management Co., Broadhi Capital, Shenzhen Blue Bay Equity Funds, and Jilin Aodong […]

Chinese Drug Maker Thousand Oaks Biopharmaceuticals Nets $44M In Series A Round appeared first on China Money Network.